
Benjamin I Binder-Markey\textsuperscript{1,2,3,4}, Wendy M Murray\textsuperscript{1,2,3,4,5}, Julius P.A. Dewald\textsuperscript{1,2,3}
\textsuperscript{1}Department of Biomedical Engineering, Northwestern University, Evanston, IL
\textsuperscript{2}Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL
\textsuperscript{3}Department of Physical Medicine and Rehabilitation Science, Northwestern University, Chicago, IL
\textsuperscript{4}Shirley Ryan AbilityLab, Chicago, IL
\textsuperscript{5}Research Service, Edward Hines Jr., VA Hospital, Hines, IL

ABSTRACT

\textbf{Background and Purpose:} Following a hemiparetic stroke, prolonged altered motor neuronal inputs may drive passive mechanical changes within muscle that further amplify the brain injury induced motor impairments, reducing optimal recovery. However, due to confounding factors, i.e. muscle hyperactivity and botulinum neurotoxin (BoNT) chemical denervation, there is no consensus on how altered neural inputs following a stroke may affect the muscle’s passive mechanical properties. Therefore, the goal of this study is to understand how passive mechanical properties of muscles adapt to prolonged altered neural inputs by minimizing and controlling for muscle hyperactivity and BoNT.

\textbf{Methods:} Passive torques about the wrist and metacarpophalangeal (MCP) joints were quantified in the paretic and non-paretic wrist/fingers of 34 individuals with chronic hemiparetic stroke. Participants’ hand impairments ranged from severe to mild and included a group who received BoNT injections. Torques were quantified with the subjects in a sleep or near-sleep state to mitigate muscle hyperactivity and EMGs were continuously monitored to ensure no muscle activity during data collection.

\textbf{Results:} Our findings indicate that the passive mechanics of wrist/fingers do not substantially change following a hemiparetic stroke unless the individual previously received BoNT injections. Substantial increases in passive flexion torques were observed in individuals who had received BoNT which resulted in a decrease of up to 68 degrees in passive MCP range of motion in extension.

\textbf{Conclusions:} To the best of our knowledge this study is the most thorough investigation of \textit{in vivo} passive elastic torques at the wrist and fingers in chronic hemiparetic stroke. The results indicate increased stiffness observed clinically and in previous studies are likely a result of muscle hyperactivity, or are the result of BoNT injections. Thus, loss of hand function post-stroke is predominately due to motor impairments post stroke suggesting future studies and rehabilitation techniques should focus on these deficits.

1 INTRODUCTION

Following a hemiparetic stroke, induced damage to the corticofugal motor (i.e., corticospinal and corticobulbar) pathways results in an increased reliance on indirect contralesional corticoreticulospinal pathways\textsuperscript{1-5}. Increased reliance on these indirect pathways alters neural input to spinal motor neurons and results in motor impairments such as weakness\textsuperscript{6-8}, loss of independent joint control\textsuperscript{9-13}, motor neuron hyperactivity that manifests as hypertonicity (a persistent muscle activity) and spasticity (i.e., hyperactive stretch reflexes)\textsuperscript{14-18}. This altered motor neuronal drive, over time, may change the mechanical structure of muscle, further amplifying brain injury induced motor impairments. One particularly detrimental sequelae of secondary structural muscle adaptations are that muscles can become increasingly stiff, making movement progressively more difficult thus preventing individuals from achieving their optimal recovery potential.

Within current literature, there is not a clear consensus regarding how prolonged exposure to the altered neural inputs that occur following a stroke affects muscle structure and its passive mechanical properties. Previous studies that have quantified muscle adaptations following a stroke have demonstrated decreased fascicle lengths\textsuperscript{19-21}, often accompanied by increased joint torques and stiffness\textsuperscript{7,19,20,22-26} providing evidence of muscle contractures and mechanical property changes following a stroke. However, there is also conflicting evidence that passive mechanical properties are not different between the paretic and non-paretic limbs of stroke survivors\textsuperscript{22,27}.

A shortcoming within many of the previous studies is the inclusion of confounding factors that could influence measurements of muscle properties, the most important factor being abnormal muscle hyperactivity. Previous studies did not properly address abnormal muscle hypertonicity resulting from motorneuron hyperactivity and associated stretch reflex hyperactivity (i.e., spasticity) during data collection. These studies either continuously moved the joint, lacked pre-

stretching of the muscles to attenuate hyperactive motoneurons28, or did not report EMGs or monitoring muscle activity during data collection. These approaches all increase the likelihood of the presence of muscle activity during data collection that can obfuscate the underlying biomechanical changes, especially during “passive” or “relaxed” conditions. Abnormal hyperactivity can have a significant effect on the “passive” resistance if not adequately considered and controlled, leading to the variability within reported outcomes.

An additional confounding variable that these previous studies do not consider is the potential long term side effects of botulinum neurotoxin (BoNT) that chemically denervates a muscle. BoNT is commonly used following a stroke to treat severe muscle hypertonicity and spasticity. However, BoNT within murine muscles causes structural changes of increased intramuscular connective tissue and increasing mechanical stiffness in the short-term and long-term29-33. If the administration of BoNT also increases intramuscular connective tissue within human muscle, it is critical to understand these changes as distinct from the effects caused by the altered neural inputs that occur following a stroke.

The goal of this study is to understand how passive mechanical properties of muscles adapt to prolonged altered neural inputs, as a result of a stroke, by minimizing and controlling for muscle hyperactivity and BoNT. We chose to study the muscles of the hand and wrist as they have the longest lasting and most severe neural deficits and impairments following a stroke34-37. To evaluate the effects over a broad gradation of altered neural inputs, we recruited individuals with severe to mild hand impairments. Finally, because the hand and wrist muscles are a frequent site of BoNT treatment, we explored the potential long-term effects of chemical denervation following BoNT on these muscles by including a subset of stroke participants with a history of BoNT treatment. Based on the findings of the previous literature and the clinical presentation of an increasingly stiff

flexed wrist and finger posture of many individuals following a stroke, the driving hypotheses for this work are that: 1) passive torques of the paretic hand will be greater than the non-paretic hand, 2) changes in joint torques will be graded with the severity of the hand impairments and 3) limbs with wrist and finger muscles that have been chemically denervated using BoNT will demonstrate greater increases in passive joint torques than those that have not.

2 MATERIALS AND METHODS

2.1 Participants

An interdepartmental research database, the Clinical Neuroscience Research Registry from Northwestern University and the Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago), was used to pre-screen individuals with chronic hemiparetic stroke based on set inclusion/exclusion criteria (Table 1) and the prior clinical assessment of upper-limb impairment recorded in the registry; wrist and finger range of motion (ROM) was not a consideration in the inclusion/exclusion of individuals. 38 individuals were enrolled in this study, 28 of the individuals had never received BoNT injections (no-BoNT) and 10 individuals had previously received BoNT injections in their forearms (BoNT-injected). All individuals who received BoNT injection had injections within their forearm flexor muscles. Because one of these 10 individuals also had BoNT injections in their forearm extensor muscles, this participant was subsequently excluded from the analysis in order to standardize injection sites to the flexor group only. Additionally, due to the inability to fully relax both their paretic and non-paretic arm muscles during data collection, the data of three individuals (two in the BoNT-injected group and 1 in the non-BoNT group) were ultimately excluded from the analysis. The remaining 34 study participants were stratified into 3 groups by hand impairment (severe (n=16; n = 7 of these from the BoNT group), moderate (n=9),

or mild (n=9)) using the Chedoke McMaster Stroke Assessment Hand Score (CMSA-HS)\textsuperscript{38} (see Table 2). CMSA-HS of 1-3 were considered severe impairments, 4-5 moderate impairments, and 6-7 mild impairments. The 7 BoNT-injected participants who were not otherwise excluded from analysis all had severe hand impairments; their clinical scores were not significantly different from those in the no-BoNT severe group in either the CMSA-HS or Modified Ashworth Scale (MAS) (p=0.196 and p=0.158, respectively) (Table 2). The clinical tests of CMSA-HS and MAS reported here were administered at the time of testing for this study by the same trained and licensed physical therapist to ensure accuracy and consistency across all participants.

The study protocol was developed in compliance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Northwestern University. Participants gave informed consent for participation using an approved form by the IRB at Northwestern University. Clinically relevant subject demographics were gathered from all participants in a brief questionnaire prior to data collection (Table 2).

2.2 Experimental Set-up

A custom built modified Wrist and Finger Torque Sensor (WFTS)\textsuperscript{39} was used to collect the torques produced about the wrist and fingers. The WFTS allows the experimenter to position the wrist and metacarpophalangeal (MCP) joints separately, in discrete 15° increments, throughout each joints range of motion while simultaneously collecting the torques about each joint. Within the device the two distal finger joints for each finger were splinted, fixing the distal joints and ensuring isolated wrist and MCP movements. Participants were seated in an upright position and their hand secured to the WFTS (Figure 1). The participant’s arm was positioned comfortably at their side so that the forearm was parallel to the ground and the hand vertical with the palm facing medially; this position eliminates the effects of gravity in the flexion and extension directions at

the wrist and fingers (Figure 1). Muscle activity was monitored throughout the trials using surface EMGs electrodes (16-channel Bagnoli EMG System, Delsys Inc., Boston, MA; 1000 x gain, 20-450 Hz bandpass) placed over 4 muscles; Flexor Digitorium Superficialis, Flexor Carpi Ulnaris, Extensor Digitorium Communis, and Extensor Carpi Radialis.

2.3 Muscle Hyperactivity Inhibition Protocol

Muscle hyperactivity was successfully reduced and quieted during data collection by having the participants in a sleep or near-sleep state throughout the protocol. Decreasing the hyperactivity of the muscles during this relaxed or near-sleep state is believed to be due to a reduced activation of the reticulospinal tract, decreasing the spinal motoneurons excitability and muscle hyperactivity allowing the muscle to be in a passive state\textsuperscript{40-42}. This state was facilitated by creating a dark relaxing atmosphere in which a video or music was played to occupy the participants and divert their attention from the experiment.

Each session began with 10-15 minutes of stretching of the shoulder, elbow, wrist, and fingers to position the participant in the device. Once in the device, an additional 10 minutes of stretching of the wrist and fingers was performed. These stretches accommodated the individual to the device as well as reduced motor neuron hyperactivity (Supplemental Figure 1).\textsuperscript{28} After the stretching protocol, the wrist and fingers were allowed to move freely and rest at their equilibrium posture by unlocking the restraints of the device. Baseline trials were collected at this equilibrium posture to zero out the device and set the passive EMG baseline during three 15-second trials where no evidence of EMG activity was present. This critical EMG baseline was used to ensure that the muscles were passive with no detectable muscle activity throughout the remainder of the experiment by using the methods described in section 2.5 below.

2.4 Experimental Procedure

The protocol was completed on two separate back-to-back days, if possible. The first day consisted of data collection from the non-paretic hand and the second day consisted of data collection from the paretic hand. Passive torques were collected throughout multiple combinations of both the wrist and MCP joint postures. The wrist posture was randomly set in 15° increments between 60° of flexion and 60° of extension, resulting in 9 wrist postures. At each of the randomly set wrist postures the MCP joints were positioned throughout their range of motion, starting in full extension moving to full flexion and back to full extension in static 15° increments. At each static position of wrist and MCP posture the data was collected for 15 seconds and visually inspected for evidence of muscle activity or torque deviations throughout the trial. If either were present the trial was discarded and another trial at that position was collected. Torques were collected at static postures in order to prevent muscle hyperactivity by eliminating the Ia afferent velocity dependent component of the stretch reflex elicited during even slow continuous motions within the chronic stroke population. MCP range of motion (ROM) was determined by the subject’s comfort level and the device’s range of motion and recorded for each individual.

2.5 Data processing:

The raw torque and EMGs were collected and digitized at a sampling frequency of 1kHz. The torque and rectified EMG data were then digitally filtered using a zero-phase infinite impulse response 4th-order Butterworth low-pass filter with a 4Hz corner frequency.

The processed baseline trials were used to set the torque offset and EMG threshold. Torque offset was set as the average torque during the three baseline trials. EMG threshold, $EMG_t$, was set as:

$$EMG_t = \bar{x}_{EMG\_base} + 3 \cdot \sigma_{EMG\_base}$$

where $\bar{x}_{EMG_{base}}$ is the average over the three EMG baseline trials and $\sigma_{EMG_{base}}$ is the average standard deviation of the EMG over the three baseline trials.

For each static passive torque trial, the processed torque and EMG data were divided into 1-second bins, a total of 15 bins per trial. In each bin the average torque and EMG value was determined, if the average EMG signal from any muscle went above $EMG_t$ or if the torque deviated more than 5% from the mode of the torques across the entire trial, the bin was discarded. The average of the remaining bins for each trial were used to create the total torque versus wrist and MCP posture data set for each subject.

2.6 Analysis of Data

To determine the effect of hand (paretic vs. non-paretic); a generalized linear-mixed model analysis was completed in SPSS (v24.0 IBM Corp Armonk, NY). We analyzed the measured wrist joint torque, MCP joint torque, and ROM of the MCP joints across all wrist angles of the participants within each group (severe BoNT-injected, severe no-BoNT, moderate, and mild). Across all the analyses, the dependent variable was either torque or ROM and data were analyzed using four factors including subject, hand (paretic/non-paretic), MCP position, and wrist position. Participants were set as a random intercept factor; all other factors were fixed factors. To test differences in the paretic hands of the two severely impaired groups (BoNT-injected vs. no-BoNT), linear-mixed model analyses were run using the same factors as before except with BoNT-injected/no-BoNT replacing paretic/non-paretic as the hand factor.

The effect size of the changes between the paretic and non-paretic hand at each impairment level were found using the average difference between torques of the paretic and non-paretic hands. The differences in torques were calculated by subtracting the torque of non-paretic from the torque of paretic hand at each combination of wrist and MCP joint posture. The difference at

A posture was only calculated if a torque was present in both the paretic and non-paretic hand. Averages and standard deviations of the differences were used in the effect size calculations.

3 DATA AVAILABILITY

The data set used within this analysis is available by request from the authors.

4 RESULTS

4.1 Measured Total Passive Torque about the Wrist and MCP joints

Across impairment levels there were no substantial increases in torque between the paretic and non-paretic hand unless the individuals had received BoNT injections in their forearm muscles. The effect sizes for the torque differences observed between hands in the BoNT-injected group were large at both the wrist and MCP joints (Cohen’s d=1.95 and 1.65, respectively). The effect sizes for the no-BoNT groups fell in the small to medium range (Cohen’s d=0.02 to 0.66) about the wrist and MCP joints, respectively.

At the MCP joints, significant differences (p<0.05) in torques were observed between the paretic and non-paretic limbs in every group. However, the only group where finger flexion torque was substantially greater in the paretic hand was the BoNT-injected group, with the effect increasing as the fingers and wrist were positioned in extended postures (Figure 2). The average differences in MCP joint torque across the severely, moderately, and mildly impaired no-BoNT groups were 8.1 Ncm, 5.0 Ncm, and 2.1 Ncm, respectively, whereas the average difference of MCP joint torque of the BoNT-injected group was 19.3 Ncm.

At the wrist, significant differences (p<0.05) in torques were observed between the paretic and non-paretic limbs in every group except the mildly impaired individuals. As with the MCP joint torques, the only group where substantial increases in wrist flexion torque of the paretic hand was observed was the BoNT-injected group (Figure 3). The average difference in wrist torques for the

severely, moderately, and mildly impaired no-BoNT groups were 0.5 Ncm, 6.7 Ncm, and 0.3 Ncm, respectively, while the average difference of torques at the wrist for the BoNT-injected group was 32.2 Ncm.

4.2 Impact on Range of motion

The BoNT-injected group had a significantly reduced passive ROM in their paretic hand as compared to their non-paretic hand (p< 0.001) with average decreases in extension across all wrist angles of 33° and a loss of 68° at full wrist extension (Figure 4a). There were no differences (p=0.360) in ROM of the no-BoNT group with comparable clinical impairment scores (Figure 4b).

5 DISCUSSION

The objective of this research was to understand how passive mechanical muscle properties adapt after prolonged changes in neural input to the muscle, as the result of stroke, while minimizing and controlling for muscle hyperactivity and potential long-term side-effects of chemical denervation following BoNT injections. In doing so, we collected a vast set of data from a cohort of chronic hemiparetic stroke individuals with mild to severe hand impairments. Furthermore, we demonstrated striking effects that BoNT, and the resulting chemical denervation, likely have on the muscle’s passive mechanical properties.

Our results indicate that prolonged altered neural motor input, as a result of a stroke, does not increase the passive mechanical properties of paretic muscles. Among participants who had never received BoNT injections, we only found small to medium effect sizes (Cohen’s d=0.02 to 0.66) at the wrist and MCP joint, respectively, for the average differences in torques between limbs (Figures 2 and 3). Thus, contrary to our first and second hypotheses, we conclude that there are no substantial increases in the passive torques in the paretic versus non-paretic wrist and finger joints.

in chronic hemiparetic stroke participants with moderate to severe hand impairments in the absence of BoNT injections.

Conversely, our results suggest BoNT injections likely have a negative effect on the passive mechanics of muscle by increasing the muscle’s stiffness. Confirming our third hypothesis, individuals who underwent BoNT-injection in the paretic forearm exhibited large increases of wrist and MCP joint torques (32.2 Ncm and 19.3 Ncm, on average, respectively) in the paretic limb. The effect size at the wrist was two orders of magnitude larger in the BoNT group than the no-BoNT group (d = 1.95 for the BoNT-injected group vs d = 0.02 for no-BoNT) and 2.5 times larger at the MCP joint (d = 1.65 for the BoNT-injected group vs d = 0.66 for no-BoNT). Consistent with the location of the BoNT injections in the wrist and finger flexors, these increases in passive torques were observed as the fingers and wrist were extended, limb positions that stretch and stress the extrinsic finger flexor and wrist flexor muscles (Figures 2 & 3).

The consequence of the increased flexion torques and muscle stiffness within the BoNT-injected group were decreases of up to 68 degrees in passive MCP range of motion, as quantified within our device (Figure 4). However, this 68-degree decrease is likely an underestimation of how much active range of motion these individuals would lose. In other studies, severely impaired individuals have demonstrated finger extensor strength decreases of up to 90% 6-8. Therefore, these individuals would be unable to generate the torques necessary to extend the fingers, causing larger losses in active range of motion. Thus, increases in passive torques following BoNT injections likely exacerbate neural deficits by severely limiting the ability to open and use the hand following stroke, limiting the recovery potential of those individuals.

5.1 Discrepancies from previous published work

Discrepancy between our findings and previous findings of substantial increases of passive joint torque and stiffness in the paretic limb following chronic stroke is likely due to differences in the methodology used to collect data and steps taken to reduce the impact of the muscle hyperactivity and separation of those who received BoNT. The previous studies reporting increases in torque of the paretic upper extremity in chronic stroke individuals all utilized continuous motion to collect the passive torques.\textsuperscript{7,24,25} This presents a problem because, even at low constant velocities, hyperactive stretch reflexes can be elicited in the paretic muscle of chronic stroke individuals.\textsuperscript{8} The effect of hyperactive stretch reflexes, even at a slow continuous velocity of 10 deg/s, can increase the torques of the paretic hand by at least 30%.\textsuperscript{8} Furthermore, many of the previous upper extremity studies fail to mention whether stretching prior to data collection was utilized to attenuate the stretch reflex.\textsuperscript{7,19,25} In the few studies where EMGs were collected and monitored, it was not explicitly stated whether EMG was used to discard trials. In some cases, the EMGs were used to decompose the contribution of active and passive torques within a dynamic analytical model, dependent on acceleration, velocity, and position, using system identification methods.\textsuperscript{7,25} This can be problematic since the underlying hyperactivity may not be considered within these models and the positional component of the stretch reflex and hypertonicity may be considered as part of the passive elastic torques, confounding the results.

The inconsistencies between our study and previous studies may underscore the importance of ensuring that there is no muscle activity, even when a subject is in a “relaxed” state. Merely asking patients to relax is likely not sufficient. Many of these individuals are unable to fully relax due to hyperexcitability of their motoneurons and resulting muscle hypertonicity. Decreasing the hypertonicity of the muscles may require significant reduction in reticulospinal tract activity by
having individuals be asleep or in a near-sleep state. By reducing reticulospinal tract activity the spinal motoneurons decrease their excitability thus decreasing muscle hypertonicity and allowing the muscle to be in as passive state.\textsuperscript{40-42} This is a critical step that future studies should consider when attempting to quantify passive mechanical adaptations of muscles within any “spastic” population.

5.2 Origin of increased torques within BoNT-injected muscles

The increased flexion torques and decreased ROM suggest that individuals who received BoNT injections undergo long lasting muscular property changes. These biomechanical changes within the muscles are likely an effect of the BoNT and not related to the neural impairments post stroke. Across all the no-BoNT groups, independent of impairment level, we did not observe substantial increases in passive torques about fingers or wrist (Figures 2b-d & 3b-d). We only observe increases in passive torques in the BoNT-injected group (Figures 2a & 3a); these individuals had comparable clinical impairment scores as the no-BoNT severe group (Figures 2b & 3b) (see limitations section for an expanded discussion on this).

The source of the increased torque following BoNT injections likely originates from increased collagen within the extra cellular matrix (ECM) and resulting increased muscle stiffness. In murine models, increases in collagen content in the ECM is present 6 months following 2 BoNT injections and potentially lasts for the lifespan of the animal.\textsuperscript{29,30,33} However, the underlying mechanism of this increased collagen content is unknown. A potential mechanism by which this increase in collagen occurs is that it is a consequence of the BoNT induced muscle paralysis. BoNT chemically denervates a muscle, therefore parallels can be drawn between the effect of BoNT on muscle and typical muscle denervation. Denervated muscle has been shown to demonstrate increases in collagen content within a month after denervation.\textsuperscript{43-46} This time frame fits well within...

the three-month timeframe of BoNT induced muscle paralysis, indicating that the muscle adaptation may occur during this time of chemical denervation and may be irreversible. The changes we observed in the BoNT-injected group were long-lasting; the average time since their last BoNT injection was over four years prior to collection of the data.

Interestingly, in the individual who was excluded from the analysis because they had also received BoNT injections within their extensor muscles of their paretic limb, we found increases in passive extensor torque as the wrist and fingers were flexed (Supplemental Figure 2), stretching the BoNT-injected extensor muscles. Increases in passive extension torque was not observed in any other group. This further implicates BoNT as the likely cause of the increases in passive joint torques since whether the flexors or the extensors were injected, the resulting increases in torque corresponded with stretching the muscles at the location of the injection. Further studies into the mechanism by which BoNT affects the muscle are necessary to enhance our understanding of the long-term effects of BoNT on muscle structure and passive mechanics.

5.3 Strength of Experimental Methods Utilized in this Study

The strength of our study lies in the rigor used to ensure passive torque collection even in individuals with hyperactive muscles. We found that having study participants in a relaxed sleep or near-sleep state was an ideal condition to reduce muscle hyperactivity and promote muscles to be truly passive. Additionally, to reduce the effects of the velocity Ia or length driven type Ia or II afferent stretch reflexes, we collected the torques at static joint postures while closely monitoring EMG signals. Any data that contained evidence of muscle activity was discarded at the time of data collection and the EMG signals were again verified during the data processing protocol. To ensure a truly passive EMG baseline reference, real-time unfiltered EMG data were analyzed and if there was any evidence of muscle activity, even firing of a single motor unit, the baseline trial
was discarded and repeated. We only monitored the EMG from superficial muscles (FPS, FCU, EDC, and ECR) and did not specifically monitor the muscles within the deep compartments of the forearm. However, it is unlikely that these deeper muscles would be selectively and differentially active from the superficial muscles. Thus, we do not believe that the deeper muscles were active and contributing substantially to the torques recorded.

5.4 Study Limitations

A limitation to our study is that we are unable to tell how the difference or lack of difference in torques are related to atrophy (loss of contractile material), adaptations of extra-cellular matrix (ECM) structure of the muscle, tendon compliance, or any combination of these changes. We do not believe atrophy would have a substantial affect because previous work has demonstrated relatively little atrophy in the paretic muscles of the index finger. Additionally, we estimated each subject’s forearm volume (by measuring forearm length, wrist circumference, and maximum forearm circumference) and verified that there was no significant difference between arms using paired t-tests (severe BoNT-inject p=0.245, severe no-BoNT p=0.244, moderate p=0.885, mild p=0.604). To evaluate this further, future studies could use magnetic resonance imaging to further quantify the muscle contractile tissue volume changes and normalize torque to contractile volume for a more precise measurement. As for adaption in the ECM or tendon, because we made measurements of joint properties, our results reflect the combined changes of all muscle-tendon units that cross each joint. Our methods do not allow evaluation of whether the observed effects are due to adaptations in muscle architecture, ECM, or tendon in the paretic limb.

Another limitation to this study was that it was a cross-sectional study, evaluating changes within individuals who previously received BoNT injections versus those who did not. It was not

a longitudinal, randomized, control study to determine whether BoNT increases muscle or joint stiffness. We also were not able to correlate dosage and usage of BoNT to increases in torques; we lacked access to the medical records of these individuals that would be needed for such an analysis. Future studies should include the use of a longitudinal study and medical records to deduce any causal or dosage dependent effects of BoNT on muscle stiffness.

Despite these limitations, we posit that the increases in torques we observed are due to residual effects following BoNT use rather than underlying differences in impairments between the groups. In support of this, clinical impairment scores of CMSA-H or MAS were not significantly different (p=0.196 and p=0.158, respectively) between the BoNT-injected and the severely impaired no-BoNT groups. The only demographic differences between the two groups were time since stroke and age at the time of collection; although age at the time of their stroke was not significantly different (p=0.618). The average time since stroke for no-BoNT individuals was 17 years whereas the average time for BoNT-injected individuals was 10.7 years. Interestingly, Botox was approved by the FDA for treatment of upper limb spasticity 7 years prior to the collection of these data48 potentially accounting for the difference between the groups. The likelihood that an individual would receive BoNT treatment may have depended on how long that individual had been living with their impairments before BoNT became an approved clinical treatment for upper limb spasticity. The difference in the average time since stroke in our two severe impairment groups may be interpretable with the assumption that individuals who were within 3-5 years of having their stroke would be more likely to try BoNT, a newly approved clinical intervention, than those who had been living with their injury for 10 or more years at the time it was approved. This potentially could have created a natural division within equally impaired individuals as to who elected to receive BoNT versus those who did not. Thus, we argue that
underlying differences in impairments are not driving the increases in torques of the BoNT-injected group.

6 SUMMARY

To the best of our knowledge the current study is the most thorough investigation of in vivo passive elastic torques at the hand in the chronic hemiparetic stroke population. Our findings indicate that, after stroke, there are not substantial increases of passive torques about either the wrist or the fingers unless an individual receives BoNT injections. Increased stiffness observed clinically and in previous studies are likely a result of neural hyperactivity resulting from increased monoaminergic neuromodulatory drive mediated via the reticulospinal tract,\textsuperscript{15,16} not from mechanical changes of the muscles or other soft tissue structures of the hand, or are the result of BoNT injections. Therefore the loss of hand function post-stroke is more likely due to weakness from voluntary activation deficits\textsuperscript{6} and impaired control of the muscles of the hand\textsuperscript{11} following disruptions of the corticofugal pathways.\textsuperscript{49,50} Future studies and rehabilitation techniques should therefore focus on the neural deficits post stroke such as weakness and motoneuron hyperactivity to achieve improved hand function. Additionally, future work should explore potential adverse effects of BoNT to determine if the risks are worth the rewards of using this treatment to reduce impairments post stroke and maximize an individual’s with hemiparetic stroke potential recovery.

7 ACKNOWLEDGMENTS

This work was supported by a Promotion of Doctoral Studies Level II Scholarship from the Foundation for Physical Therapy, American Heart Association Pre-Doctoral Fellowship: 16PRE30970010, National Institutes of Health (T32EB009406) to J.P.A.D., and National Institutes of Health Grant R01HD084009 to J.P.A.D. and W.M.M. (principal investigators).


32. Yucesoy CA, Ates F. BTX-A has notable effects contradicting some treatment aims in the rat triceps surae compartment, which are not confined to the muscles injected. *J Biomech*. 2018;66:78-85.


![Experimental setup image](image)

**Figure 1:** Image of the experimental set up with a participant seated upright and their hand secured within the custom built modified Wrist and Finger Torque Sensor (WFTS). The participant’s arm was positioned comfortably at their side so that the forearm was parallel to the ground and the hand vertical with the palm facing medially; in this position the effect of gravity is eliminated for both the wrist and Metacarpophalangeal (MCP) torque sensors. To prevent movements of the distal finger joints during testing, the two distal finger joints were splinted within the WFTS. Muscle activity was monitored throughout the trials using surface EMGs electrodes placed over 4 muscles. The electrodes for the Extensor Digitorium Communis and Extensor Carpi Radialis are visible on the posterior side of the forearm. The electrodes for the Flexor Digitorium Superficialis and Flexor Carpi Ulnaris are not visible on the anterior side of the forearm.

Total Finger Torque Data

Figure 2: Metacarpophalangeal (MCP) torque data measured in the paretic (red) and non-paretic (blue) limb over the MCP joints’ range of motion for the (a) BoNT-injected, and no-BoNT (b) severely, (c) moderately, and (d) mildly impaired groups. The wrist joint was locked in -60 (top row), -30, 0, and 60 degrees flexion (bottom row). Error bars indicate standard error. Negative MCP angles indicate extension, positive indicate flexion; negative MCP torques indicate extension; positive indicate flexion While significant differences (* denotes p<0.05) in torques measured in paretic vs non-paretic limbs were observed in every group, the only group where finger flexion torque was greater in the paretic hand was the BoNT-injected group, with the effect increasing as the fingers were positioned in an extended posture. Data points are only displayed when there is individual data for 3 or more participants at that specific posture.

Figure 3: Wrist torque data measured in the paretic (red) and non-paretic (blue) limb over the wrist’s range of motion for the (a) BoNT-injected, and no-BoNT (b) severely, (c) moderately, and (d) mildly impaired groups. MCP joints were locked in -60 (top row), 0, and 75 degrees flexion (bottom row). Error bars indicate standard error. Negative wrist angles indicate extension, positive indicate flexion; negative wrist torques indicate extension; positive indicate flexion. While significant differences (*) denotes p<0.05) in torques measured in paretic vs non-paretic limbs were observed in every group except mildly impaired individuals, the only group where increases in wrist flexion torque of the paretic hand were observed was the BoNT-injected group. Data points are only displayed when there is individual data for 3 or more participants at that specific posture.
Extension End MCP Range-of-Motion Throughout Wrist Postures

Figure 4: End of metacarpophalangeal (MCP) passive range of motion in extension throughout the wrist’s ROM for the paretic (red) and non-paretic (blue) hands of the (a) BoNT-injected severe group and (b) no-BoNT severe group. ROM was measured within the experimental device, data show the average across all participants in the group with standard error bars. The ROM of the paretic hand of the BoNT-injected was significantly and substantially less than the non-paretic hand. ROM of the BoNT-injected hand was also narrower than that observed for the paretic hand of the no-BoNT group. The greatest decreases in MCP ROM occurred in extended wrist postures. (* denotes p <0.001 between paretic v non-paretic hands within group)

**Table 1: Table of Inclusion/Exclusion Criteria for Participants**

<table>
<thead>
<tr>
<th>Subject Inclusion Criteria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke occurred at least one year prior to participation in the study</td>
<td></td>
</tr>
<tr>
<td>Paralysis confined to one side of the body</td>
<td></td>
</tr>
<tr>
<td>Ability to give informed consent</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subject Exclusion Criteria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke occurred in the cerebellum or brainstem</td>
<td></td>
</tr>
<tr>
<td>Impairment or injury in the unimpaired limb</td>
<td></td>
</tr>
<tr>
<td>Severe atrophy of the impaired limb</td>
<td></td>
</tr>
<tr>
<td>Severe concurrent medical problems</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Subject Demographics.
(CMHS – Chedoke McMaster Stroke Assessment Hand Score, MAS – Modified Ashworth Scale)

<table>
<thead>
<tr>
<th>Impairment Level</th>
<th>Sex</th>
<th>Age in years (SD)</th>
<th>Time Since Stroke in years (SD)</th>
<th>Age at time of stroke in years (SD)</th>
<th>Paretic Side</th>
<th>CMHS</th>
<th>MAS</th>
<th>Time Since Last BoNT Injection in years (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BoNT-Injected Severe (n=7)</td>
<td>6-M, 1-F</td>
<td>56.7 (8.3)</td>
<td>10.7 (5.3)</td>
<td>46.0 (5.1)</td>
<td>4-L, 3-R</td>
<td>2.85 (0.38)</td>
<td>2.71 (0.48)</td>
<td>4.5 (2.8)</td>
</tr>
<tr>
<td>No-BoNT Severe (n=9)</td>
<td>6-M, 3-F</td>
<td>60.28 (10.40)</td>
<td>17.1 (7.91)</td>
<td>43.2 (13.6)</td>
<td>5-L, 4-R</td>
<td>2.44 (0.73)</td>
<td>2.17 (0.87)</td>
<td></td>
</tr>
<tr>
<td>Moderate (n=9)</td>
<td>5-M, 4-F</td>
<td>64.3 (7.95)</td>
<td>13.2 (7.96)</td>
<td>51.1 (12.5)</td>
<td>6-L, 3-R</td>
<td>4.22 (0.44)</td>
<td>1.78 (0.94)</td>
<td></td>
</tr>
<tr>
<td>Mild (n=9)</td>
<td>5-M, 4-F</td>
<td>56.93 (12.18)</td>
<td>8.41 (3.71)</td>
<td>48.5 (9.8)</td>
<td>1-L, 8-R</td>
<td>6.44 (0.53)</td>
<td>0.28 (0.57)</td>
<td></td>
</tr>
</tbody>
</table>